Over the past several years, new tools have helped interventional cardiologists capture patients who historically would have been candidates for surgery. Drug-eluting stents are apt to only increase this trend. These technology innovations have sparked the latest round of proclamations that there is no future in cardiac surgery since the sector's largest component--bypass--is waning, and that the only worthwhile coronary device investment opportunities lie in products with interventional applications. Yet cardiac surgery remains a major device opportunity. A significant increase in M&A activity and recent later-round financings by companies like Percardia and Converge indicate that investing in cardiac surgery start-ups remains alive and well, albeit with new challenges. Indeed, some investors believe that heart surgeons, traditionally conservative adopters of new technology, are now more receptive than ever to new devices and procedures because of the threat to their livelihoods posed by interventionalists' increased encroaching on surgeons' core patients.
By Stephen Levin
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
New continuous glucose monitoring manufacturing site in Indiana is part of Roche’s plan to boost its US presence. Roche’s launch of Accu-Chek SmartGuide system last year with AI-powered prediction capabilities puts it as a key differentiator from competitors such as Abbott and Dexcom.
Diabetes company Insulet announced that former longtime J&J executive Ashley McEvoy will succeed Jim Hollingshead as president and CEO effective today. Analysts applauded the appointment, noting McEvoy’s strong background in medtech and diabetes.
Cambridge-based startup Mursla Bio's liquid biopsy test EvoLiver uses extracellular vesicles to detect hepatocellular carcinoma (HCC) in high-risk cirrhotic patients. Medtech Insight sat down with with Mursla Bio CEO Pierre Arsène.
OneCell Diagnostics, the Mumbai-based startup backed with $16m in series A funding, is rebranding to 1Cell.Ai to represent the firm's focus on combining deep science with AI-powered capabilities.
Medtronic says results from a recent study on the Hugo robotic-assisted surgery system substantiate its safety and effectiveness for various urological procedures. The company also announced it has submitted the system to the FDA for approval for a urological indication.
While Roche continues to view China as a strategic growth market, a sharp 23% decline in Chinese diagnostics sales offset gains in other regions and segments. Despite near-term headwinds, Roche is betting on strong instrument placement growth across its Core Lab, Molecular, and Near Patient Care segments to fuel future demand for consumables and services–key components of its long-term medtech strategy.
New continuous glucose monitoring manufacturing site in Indiana is part of Roche’s plan to boost its US presence. Roche’s launch of Accu-Chek SmartGuide system last year with AI-powered prediction capabilities puts it as a key differentiator from competitors such as Abbott and Dexcom.
